A new Gene Therapy publication details the safety and biodistribution assessment of SPVN06, a mutation-independent gene therapy in development for rod–cone dystrophies (RCDs). These inherited retinal disorders are a leading cause of vision loss and can result from mutations in more than 100 different genes, which makes developing broadly applicable treatments challenging. SPVN06 is an…
A new study from the National Institutes of Health (NIH) has shown promising results for reserpine—a medication originally approved in 1955 for high blood pressure—as a potential treatment to prevent vision loss caused by inherited blinding diseases such as retinitis pigmentosa. In preclinical studies, reserpine protected retinal neurons essential for vision, particularly in females. Unlike…
We’re proud to share that EyeCRO CEO Dr. Rafal Farjo is a co-author on a new publication validating a cell-based potency assay for LUXTURNA®, the first gene therapy approved in the U.S. for an inherited retinal disease. As stated in the publication: “This represents the first report of validation studies supporting an in vitro cell-based…
We are thrilled to announce the publication of our latest research in eLife. This milestone represents an inspiring collaboration between EyeCRO and the esteemed laboratory of Dr. Anand Swaroop at the National Eye Institute. Our partnership exemplifies how teamwork and shared vision can advance the frontiers of science and medicine, particularly in the development of…
In the article “Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush,” published in Pharmaceuticals, Volume 17, Issue 6 (June 2024), scientists explored the impact of BDNF on retinal structure and visual function. The study focused on rodent models to investigate how BDNF affects retinal ganglion…
We are excited to announce that our CEO, Rafal Farjo, Ph.D., has been named the ARVO Foundation for Eye Research Chair. This prestigious appointment highlights Dr. Farjo’s extensive experience and dedication to advancing ocular research over the past 25 years. As the CEO of EyeCRO, Dr. Farjo has been instrumental in helping clients develop new…
We are proud to announce a significant breakthrough in ophthalmic care: our innovative MiDROPS® technology has been validated for safety and efficacy in its first clinical application. Data from the technology’s first clinical application is being presented at the 96th meeting of the Association for Research in Vision and Ophthalmology in Seattle, WA. Read the…
EyeCRO is thrilled to announce the first clinical application of our groundbreaking MiDROPS® technology.
“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release
EyeCRO scientist Jarrod Harman contributed to a paper focused on X-linked juvenile retinoschisis published in Experimental Eye Research. This paper expands the mechanistic understanding of XLRS. Read the full paper here https://www.sciencedirect.com/science/article/pii/S0014483523002129?dgcid=coauthor